SCHEMBL312265

SCHEMBL312265

O=c1cc(-c2ccc(O)cc2)[nH]c2ccc(F)cc12

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.74
ALDH1A1 P00352 10/20 0.73
HPGD P15428 9/20 0.73
KDM4E B2RXH2 7/20 0.73
LMNA P02545 6/20 0.73
MEN1 O00255 7/20 0.68
KMT2A Q03164 7/20 0.68
CTSV O60911 1/20 0.61
CTSL P07711 1/20 0.61
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
MAPK1 P28482 2/20 0.55
THRB P10828 2/20 0.55
KEAP1 Q14145 1/20 0.54
NFE2L2 Q16236 1/20 0.54
MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311823 0.88 KDM4E (0.74) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA
SCHEMBL312000 0.87 HPGD (0.61) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA
SCHEMBL6534299 0.84 HPGD (1.00) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA
SCHEMBL312025 0.83 KDM4E (0.51) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA
SCHEMBL6295964 0.80 ALDH1A1 (0.81) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA
SCHEMBL311524 0.80 CTSV (0.75) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA
SCHEMBL311852 0.80 KDM4E (0.51) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA
SCHEMBL31552890 0.80 KDM4E (0.51) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA
SCHEMBL25910968 0.78 KDM4E (0.55) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA
SCHEMBL339089 0.78 RAB9A (0.55) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 SMN1; SMN2 2736/4885ALDH1A1 1211/4885HPGD 138/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 SMN1; SMN2 2736/4885ALDH1A1 1211/4885HPGD 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.